Status:
COMPLETED
A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study compares LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs are given by injection under the skin of the abdomen. The study will be conducted in healthy peo...
Eligibility Criteria
Inclusion
- Healthy male or a female (not pregnant and agreeable to take birth control measures until one month after study completion)
- Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)
- Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results
- Are nonsmokers, have not smoked for at least 6 months prior to entering the study
Exclusion
- Are currently participating in or completed a clinical trial within the last 30 days
- Have previously participated or withdrawn from this study
- Have donated blood or have blood loss of more than 500 mL within the past 3 months
Key Trial Info
Start Date :
October 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 6 2018
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03286751
Start Date
October 13 2017
End Date
February 6 2018
Last Update
May 1 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Mainz, Germany, 55116
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Neuss, Germany, 41460